Skip to main content

Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians Cover

.blurhash-client-img { display: none !important; }

Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians

Romanian Journal of Internal Medicine

Volume 58 (2020): Issue 4 (December 2020)

By: Sean Sileno, Razvan M. Chirila and Dana M. Harris

Open Access

|Dec 2020

Abstract

Patients with chronic liver disease have associated comorbidities that require treatment, including cardiovascular disease, arrhythmias, cerebrovascular accidents and pain. These medications may affect the liver disease. Due to the complexity of medical problems in patients with chronic liver disease, treating clinicians benefit from targeted guidance for their care.

References

1. ASRANI S., DEVARBHAVI H., EATON J., KAMATH P. Burden of liver diseases in the world. J Hepatol. 2019; 70(1):151–171.10.1016/j.jhep.2018.09.01430266282
Search in Google Scholar Back to article
2. PIMPIN L., CORTEZ-PINTO H., NEGRO F. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718–735.10.1016/j.jhep.2018.05.01129777749
Search in Google Scholar Back to article
3. CHEDID, M. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA. Dig Dis Sci. 2017; 62:2621–2622.10.1007/s10620-017-4724-628840385
Search in Google Scholar Back to article
4. DOYCHEVA I., WATT K., RIFAI G. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017; 62(5):1373–1380.10.1007/s10620-017-4492-328194666
Search in Google Scholar Back to article
5. HEIDELBAUGH J., BRUDERLY M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74(5):756–762.
Search in Google Scholar Back to article
6. YOUNOSSI Z., STEPANOVA M., YOUNOSSI Y., GOLABI P., MISHRA A., RAFIQ N., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020; 69:564–568.10.1136/gutjnl-2019-31881331366455
Search in Google Scholar Back to article
7. SCHIERWAGEN R., USCHNER F., MAGDALENO F., KLEIN S.,TREBICKA J. Rationale for the use of statins in liver disease. Am J Physiol Liver Physiol. 2017; 312:407–412.10.1152/ajpgi.00441.201628280144
Search in Google Scholar Back to article
8. MOCTEZUMA-VELAZQUEZ C., ABRALDES J., MONTANO-LOZA A. The Use of Statins in Patients with Chronic Liver Disease. Curr Treat Options Gastro. 2018; 16:226–240.10.1007/s11938-018-0180-429572618
Search in Google Scholar Back to article
9. VARGAS J., ARRESE M., SHAH V., ARAB J. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep. 2017; 19(9):43.10.1007/s11894-017-0584-7582268628752475
Search in Google Scholar Back to article
10. JANICKO M., DRAZILOVA S., PELLA D., FEDACKO J., JERCUSKA P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016; 22(27):6201–6213.10.3748/wjg.v22.i27.6201494597927468210
Search in Google Scholar Back to article
11. KUMAR S., GRACE N., QAMAR A. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. Dig Dis Sci. 2104; 59:1958–1965.10.1007/s10620-014-3179-224838495
Search in Google Scholar Back to article
12. SAKAMOTO K., KIMURA J. Mechanism of Statin-Induced Rhabdomyolysis. J Pharmacol Sci. 2013; 123:289–294.10.1254/jphs.13R06CP24257439
Search in Google Scholar Back to article
13. FARIGON, S., PORZIO, M., FRACANZANI A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37)13306–13324.10.3748/wjg.v20.i37.13306418888825309067
Search in Google Scholar Back to article
14. DONGIOVANNI P., PETTA A., MANNISTRO V., MANCINA R., PIPITONE R., VALENTI L., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015; 63:705–712.10.1016/j.jhep.2015.05.00625980762
Search in Google Scholar Back to article
15. IKEDA M., ABEK., YAMADA M., DANSAKO H., KATO N. Different anti-HCV profiles for statins and their potential for combination therapy with interferon. Hepatology. 2006; 44(1):117–125.10.1002/hep.2123216799963
Search in Google Scholar Back to article
16. ABRALDES, J., VILLANUEVA C., ARACIL C., TURNES J., HERNANDEZ-GUERRA M., et a;. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016; 150:1160–1170.10.1053/j.gastro.2016.01.00426774179
Search in Google Scholar Back to article
17. SIMON T., BONILLA H., CHUNG R., BUTT A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients hepatitis c virus: results from ERCHIVES. Hepatology. 2016; 64(1):47–57.10.1002/hep.28506491743826891205
Search in Google Scholar Back to article
18. KAWATA S., YAMASAKI E., NAGASE T., INUI Y., ITO N., MATSUDA Y., et al. Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. A Randomized Control Trial.Br J Cancer. 2001; 84:886–891.10.1054/bjoc.2000.1716236383811286466
Search in Google Scholar Back to article
19. CONNOLLY S. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100(19):2025.10.1161/01.CIR.100.19.202510556230
Search in Google Scholar Back to article
20. BABATIN, M., LEE S., POLLAK P. Amiodarone Hepatotoxicity. Current Vascular Pharmacology. 2008; 6:228–236.10.2174/15701610878491201918673162
Search in Google Scholar Back to article
21. POLLACK P., BOUILLON T., SHAFER S. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 200; 67:642–652.10.1067/mcp.2000.10704710872646
Search in Google Scholar Back to article
22. MATTAR W., GADUS-PIZLO I., KWO P. Amiodarone Hepatotoxicity in the Context of the Metabolic Syndrome and Right-sided Heart Failure. Gastrointestin Liver Dis. 2009; 18(4):419–423.
Search in Google Scholar Back to article
23. PENDYALA V. A case of Amiodarone-induced Hepatitis and Review of the Literature. J Hepatol Gastroint Dis. 2016; 2:120.
Search in Google Scholar Back to article
24. SUNG P., YOON S. Amiodarone Hepatotoxicity. Hepatology. 2012; 1:326.
Search in Google Scholar Back to article
25. LEWIS J., RANARD R., CARUSO A., JACKSON L., MULLICK F., ISHAK K., et al. Amiodarone hepatotoxicity: prevalence and clincopathologic correlations among 104 patients. Hepatology. 1989; 9:679–685.10.1002/hep.18400905042785079
Search in Google Scholar Back to article
26. ATIQ M., DAVIS J., LAMPS L., BLENAD S., ROSE L. Amiodarone induced liver cirrhosis, Report of two cases. J Gastrointestin Liver Dis. 2009; 18:233–235.
Search in Google Scholar Back to article
27. GOLDSCHLAGER N., EPSTEIN A., NACCARELLI G., OLSHANSKY B., SINGHB. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000; 160:1741–1748.10.1001/archinte.160.12.174110871966
Search in Google Scholar Back to article
28. KUM L., CHAN W., HUI H., WONG G., HO S., SANDERSON J., et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese Patients with or without baseline liver dysfunction. Clin Cardiol. 2006; 29:295–299.10.1002/clc.4960290705665391216881537
Search in Google Scholar Back to article
29. TRIPODI A., MUNUCCIP. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147–156.10.1056/NEJMra101117021751907
Search in Google Scholar Back to article
30. QAMAR A., VADUGANATHAN M., GREENBERGER N., GIUGLIANO R. Oral anticoagulants in patients with liver disease. JAM Coll Cardiol. 2018; 71(19)2162–2175.10.1016/j.jacc.2018.03.02329747837
Search in Google Scholar Back to article
31. LING K., CHAO T., LIU C., LIN Y., CHANG S., LO L., HU Y., TUAN, T., et al. Liver cirrhosis in patient with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Herat Assoc. 2017; 6(6).10.1161/JAHA.116.005307566916228645935
Search in Google Scholar Back to article
32. GORIACKO P. VELTRI K. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018; 100(5):488–493.10.1111/ejh.1304529444357
Search in Google Scholar Back to article
33. HUM J., SHATZEL J., JOU J., DELOUGHERY T. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017; 98:393–397.10.1111/ejh.1284428009449
Search in Google Scholar Back to article
34. INTAGLIATA N., HENRY Z., MAITLAND H., SHAH N., MATILANDS H., SHAH N., ARGO C., NORTHUP P., CALDWELL S. Direct oral anticoagulants in cirrhosis patient pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016; 61:1721–1727.10.1007/s10620-015-4012-226725062
Search in Google Scholar Back to article
35. MALESPIN M. Risk of nonsteroidal anti-inflammatory drugs and safety of acetaminophen in patients with advanced liver disease. Clin Liver Dis. 2018; 12(3):85–88.10.1002/cld.737638591330988918
Search in Google Scholar Back to article
36. CHANDOK N., WATT K. Pain management in the cirrhotic patient: The clinical challenge. Mayo Clin Proc. 2010; 85(5):451–458.10.4065/mcp.2009.0534286197520357277
Search in Google Scholar Back to article
37. Eliquis (apixaban) [package insert]. Bristol-Myers Squibb. New York, NY; 11/2019. [cited May 14/2020]. Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf.
Search in Google Scholar Back to article
38. Pradaxa (dabigatran etexilate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT; 11/2019 [cited May 14, 2020]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
Search in Google Scholar Back to article
39. Savaysa (edoxaban) [package insert]. Daiichi Sankyo. Tokyo, Japan. 1/2015 [cited May 14/2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
Search in Google Scholar Back to article
40. Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc. Titusville, NJ; 03/2020 [cited May 14/2020]. Available from: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/rjim-2020-0018 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English

Page range: 181 - 187

Submitted on: Jun 4, 2020

|

Published on: Dec 17, 2020

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

aminotransferases,

recommendations

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2020 Sean Sileno, Razvan M. Chirila, Dana M. Harris, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 58 (2020): Issue 4 (December 2020)